Combination of Osimertinib and Bevacizumab as First-line Treatment for Patients With Metastatic EGFR-Mutant Lung Cancers—Reply

In Reply We thank Qi and colleagues for their careful review of our article and their thoughtful comments. We agree that the progression-free survival (PFS) of the osimertinib and bevacizumab combination seen in our study¹ is comparable to the median PFS with osimertinib alone in the FLAURA study.² In our article, we note that there was a larger proportion of patients with preexisting brain metastases compared with the FLAURA population (31% vs 19%), and 16% of patients withdrew consent without progression and unrelated to toxic effects to pursue consolidative local therapy (n = 4) or continue with commercial osimertinib (n = 4). These factors may have influenced the PFS in our study.